Lutikizumab
- Generic Name
- Lutikizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1791411-57-8
- Unique Ingredient Identifier
- 15FAZ725S0
- Background
Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT06548542
- Locations
- 🇫🇷
Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud /ID# 266851, Pierre Benite, Rhone, France
🇫🇷Hôpital Saint Antoine /ID# 265725, Paris, France
🇷🇸General Hospital Djordje Joanovic /ID# 266040, Zrenjanin, Vojvodina, Serbia
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1280
- Registration Number
- NCT06468228
- Locations
- 🇮🇱
Rambam Health Care Campus /ID# 262994, Haifa, Israel
🇰🇷Hallym University Kangnam Sacred Heart Hospital /ID# 264226, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇨🇳Taichung Veterans General Hospital /ID# 270741, Taichung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.